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Abstract
Background: Serum levels of novel hydroxy polyunsaturated ultra long-chain fatty acids (hPULCFAs) have been
previously shown to be reduced in pre-treatment CRC patients compared to disease-free subjects, independent of
disease stage. However, whether reduced levels of hPULCFAs result from the presence of cancer is currently
unknown, as is the distribution of hPULCFAs in the general population. The following studies were carried out to
assess whether conventional therapy would result in restoration of systemic hPULCFAs in CRC patients, and to
investigate the relationship between hPULCFA levels and age.
Methods: Tandem mass spectrometry was used to determine serum levels of the 28 carbon-containing hPULCFA
C28H46O4 (CRC-446) in the following cohorts: two independent Japanese CRC populations following surgical
tumor removal (n = 86), a North American Caucasian CRC cohort (n = 150) following post-surgery combination
chemo/radiation therapy, 990 randomly selected anonymized serum samples from subjects ranging between 11
and 99 years of age, as well as longitudinally collected serum samples from healthy normals (n = 8, up to 90
weeks) and stage IV CRC subjects on combination therapy (n = 12, up to 63 weeks).
Results: Serum CRC-446 levels in CRC subjects were significantly lower than controls (mean of 0.297 ± 0.07 ug/ml
in controls versus 0.092 ± 0.03 in CRCs, p < 0.001), and were unaffected by surgical tumor removal or by chemo/
radiation treatment (p > 0.05 between pre vs post surgery). CRC-446 levels showed a strong inverse association
with age (p < E-11) across the randomly-selected cohort of 990 subjects, with no correlation observed in the CRC-
positive subjects. Longitudinal intra-subject results, however, showed relatively stable CRC-446 levels over the short
term of up to 90 weeks in both disease-free subjects and late-stage CRC patients.
Conclusions: Our findings show that CRC-446 levels are not affected by conventional CRC treatment and inversely
correlate with age, which suggest that reduced serum CRC-446 levels likely exist prior to the development of CRC.
Extrapolation of the results to a simple screening scenario showed that, compared to fecal blood testing, pre-
colonoscopy screening using serum CRC-446 levels would require 80% fewer colonoscopies, would identify risk in
subjects under the age of 50, and would result in increased numbers of early cases detected. The precise role
these serum metabolites play in the aetiology of cancer development remains to be determined.
Background
Colorectal cancer (CRC) incidence, similar to many
other diseases, shows a strong positive association with
age. It is generally accepted that screening for colon
cancer starting at age 50 should result in reduced mor-
tality [1-4]. Many of the current screening approaches
are based on either direct colonoscopic visualization of
preneoplastic polyps, or on tumor-related markers such
as fecal occult blood [5,6], tumor-derived transcripts [7],
proteins [8-10], or methylation patterns [11], which
would presumably require a threshold tumor burden
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any medium, provided the original work is properly cited.before they could be to be used to positively detect can-
cer. Given that sporadic CRC risk is heavily influenced
by factors such as age, diet, lifestyle and environment
[12,13], all of which have metabolic implications, we
hypothesized that there should be an underlying meta-
bolic component associated with CRC. Using a compre-
hensive metabolomic approach we previously showed
that serum from CRC patients exhibited reduced levels
of novel 28 carbon long-chain hydroxy fatty acids com-
pared to disease-free controls [14]. The decreased con-
centration of these molecules, named hydroxylated
polyunsaturated ultra-long chain fatty acids (hPULC-
FAs), was observed in five separate case-control cohorts,
was independent of ethnicity or geographic location,
and showed little to no correlation with disease
stage [14].
These data, combined with the structural resemblance
of hPULCFAs to other endogenous long-chain fatty
acids with inflammation-resolving activity [15-20], sug-
gested to us that the observed reduction could be inde-
pendent of, and possibly precede, tumor development.
We herein more thoroughly investigate this hypothesis
by addressing two fundamentally important questions:
1) are reduced CRC-446 levels in CRC patients the
result of the tumor, and 2) do CRC-446 levels correlate
with age? The findings of these studies were then used
to model and discuss how a screening program based
on the measurement of CRC-446 in serum could be
used to identify high risk subjects, and what effect this
would have on existing endoscopy resources and current
CRC detection rates.
Methods
Patient sample selection
Samples provided by Osaka Medical University (Osaka,
Japan) included 46 pre-surgery CRC patients, 34 post-
surgery samples from the same pre-surgery group, and
35 controls which were prospectively collected accord-
ing to the standard collection protocol of the institution.
All samples were properly consented and study proto-
cols were performed according to the ethical guidelines
set by the committee of the three Ministries of the Japa-
nese Government. Samples from Chiba University
(Chiba, Japan), included 40 pre-surgery CRC patients,
40 post-surgery samples from the same subjects, and 40
controls. All samples were also consented and prospec-
tively collected under an ethics reviewed protocol
approved by the Institutional Review Board of Graduate
School of Medicine, Chiba University. A summary of
the populations is shown in Table 1. All samples were
processed and analyzed in a randomized manner, and
the results unblinded following analysis. hPULCFA dis-
covery results including CRC-446 on the controls and
pre-surgery Japanese samples were also previously
reported [14]. Serum samples for the age-association
study were provided as anonymized reference samples
from the Saskatchewan Disease Control Lab (SDCL,
Regina, Saskatchewan, Canada) in accordance with
SDCL policies and under a protocol approved by the
Ethics Department of the University of Saskatchewan.
Serum samples for longitudinal analysis in CRC-free
subjects were properly consented and collected accord-
ing to standard operating procedures at Phreedom
Santé, Inc., Saskatoon, Saskatchewan, Canada. Longitu-
dinal samples from stage IV metastatic subjects were
properly consented and collected under an ethically
approved clinical trial protocol by Biomira Inc., Edmon-
ton, Alberta, Canada. Serum samples from North Amer-
ican Caucasian CRC patients were collected, processed
and stored in a consistent manner by teams of physi-
cians as part of a global initiative using standardized
protocols and operating procedures at BioServe Bio-
technologies, Inc., Laurel, Maryland, USA. Collection
protocols were approved by the Western Institutional
Review Board, and all samples were properly consented.
All samples were accompanied by detailed pathology
reports which were independently verified by certified
pathologists.
Sample extraction and mass spectrometry analysis
Serum samples were stored at -80°C until thawed for
analysis, and were only thawed once. All extractions
were performed on ice as previously described [14].
Briefly, 10 ug/ml [
13C1] cholic acid was added to the
serum prior to extraction and the samples sequentially
extracting using equal volumes of serum with 1%
ammonium hydroxide and ethyl acetate (EtOAc) four
times. Samples were centrifuged between extractions at
4°C for 10 min at 3500 rpm, and the organic layer was
transferred and pooled to a new tube (extract A) for
each sample. 100 uL of the extract A were injected by
flow-injection analysis into the 4000QTRAP™ equipped
with a TurboV™ source with an APCI probe as pre-
viously described [14]. The method is based on the mul-
tiple reaction monitoring (MRM) of one parent ion
transition for hPULCFA C28H46O4 (CRC-446, 445.3/
383.4 [M-H] Da), and a single transition for the internal
standard (408.3/343.4 [M-H] Da). Metabolite concentra-
tions represented as [
13C1] cholic acid equivalents
(CAEs) were then extrapolated, normalized by dividing
by the percent recovery, and multiplied by appropriate
extraction dilution factor to yield a final serum concen-
tration equivalent.
Statistical analysis
Tandem mass spectrometry data was analysed using
JMP version 8.0.1 and Microsoft Excel. Two-tailed
unpaired Student’s t-tests were used for determination
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less than 0.05 were considered significant. Receiver-
operator characteristic (ROC) curves were generated
using JROCFIT 1.0.2 (http://www.jrocfit.org).
Results
CRC-446 levels following surgery
To investigate whether reduced CRC-446 levels in CRC
patients were the result of tumor burden (i.e., does the
tumor itself utilize or metabolize hPULCFAs), levels in
CRC patients prior to and following surgery were deter-
mined to see if tumor removal would result in CRC-446
restoration. Serum levels of CRC-446 were assayed
using tandem mass spectrometry (and reported as cholic
acid equivalents; see materials and methods) for samples
from two separate cohorts of CRC patients prior to and
following surgical tumor removal as well as matched
controls. Consistent with previous findings [14], the
CRC patient pretreatment CRC-446 levels in both the
Osaka and Chiba studies showed significantly lower (p <
0.001) levels than their respective control groups. The
mean CRC-446 level in the Osaka study control group
was 0.20 ± 0.014 ug/ml CAEs while the CRC pre-sur-
gery mean was 0.077 ± 0.006 ug/ml CAEs. The Chiba
CRC-446 control mean was 0.31 ± 0.02 ug/ml CAEs
and the presurgery mean was 0.089 ± 0.006 ug/ml
CAEs. In both patient cohorts (34 post-surgery from
Osaka, and 40 post-surgery from Chiba), CRC patients
showed statistically similar mean CRC-446 levels before
and after surgery (Figures 1A and 1B respectively, p >
0.05 for pre-versus post-surgery in both studies). The
mean CRC-446 level following surgery in the Osaka
study was 0.075 ± 0.012 ug/ml CAEs and in the Chiba
post-surgery group it was 0.072 ± 0.006 ug/ml CAEs.
For both studies, the means of the differences between
the pre- and post-surgery CRC-446 levels were zero,
and there was no correlation between CRC-446 level
and time of collection following surgery (up to 377 days
after surgery; not shown). The results showed that surgi-
cal removal of CRC tumors in patients did not result in
the restoration of CRC-446 levels.
CRC-446 levels following combination surgery/chemo/
radiation therapy
To further investigate possible effects of tumor burden,
CRC-446 levels were measured in 150 North American
Caucasian CRC patients following various combinations of
chemo and radiation therapy following surgery (Table 1).
Table 1 Summary of clinical populations
SDCL Longitudinal 1 Longitudinal 2 North American Osaka Chiba
Disease status Controls Controls CRC CRC CRC
1 Control
1 CRC
1 Control
1
Total Subjects 990 8 (110 samples) 12 (94 samples) 150 46 35 40 40
Ethnicity Caucasian Caucasian Caucasian Caucasian Japanese Japanese Japanese Japanese
<age 40 214 6
age 40-49 175 11
age 50-59 189 33
age 60-69 164 47
age 70-79 133 34
age >80 116 19
Male N 320 4 75 27 na 19 24
Male Age Range (yrs) 6-93 36-61 66 (33-91) 63 (28-90) na 68 (45-91) 48 (36-69)
Female N 670 4 75 19 na 21 16
Female Age Range (yrs) 11-99 33-44 63 (31-89) 65 (31-77) na 70 (51-84) 49 (39-59)
Stage 0/I 12 10 9
Stage II 30 14 18
Stage III 46 12 11
Stage IV 42 8 2
Unknown 20 2 0
Total surgery 139 34
2 40
2
Chemotherapy
3 76 na na
Chemo/Radiation
3 31 na na
No Chemo/Radiation
3 37 na na
No Surgery 11 na na
1Control and pre-treatment samples are the same ones reported in [11].
2Not previously reported.
3Therapy following surgery.
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761 age-matched North American subjects from the
SDCL general population described below, which showed
a reference mean CRC-446 concentration of 0.33 ± 0.005
ug/ml CAEs. Relatively low CRC-446 levels were observed
across the post-treatment CRC-positive cohort, with
a mean level of 0.15 ± 0.008 ug/ml CAEs. The correspond-
ing receiver-operator characteristic (ROC) curve is shown
in Figure 2A, which resulted in an area under the curve
(AUC) of 0.88. No correlation between CRC-446 levels
and disease stage was observed (all stage comparisons p >
0.05, Figure 2B). These levels were consistent with pre-
viously reported North American Caucasian cohort data
where pre-treatment CRC levels were reported to be
approximately 0.13 ug/ml (CAEs), with an ROC AUC of
0.876 [14]. In the current North American post-treatment
CRC cohort, we observed no correlation between CRC-
446 levels and gender, age or BMI (all p > 0.05; not
shown). Comparison of five subsets of treatment groups
within the patient cohort including those who had surgery,
those who did not have surgery, those of the patients that
did have surgery who subsequently had chemo, combina-
tion chemo/radiation, or no chemo/radiation, revealed no
significant differences in the levels of CRC-446 between
any of the treatment combinations (Figure 2C; p > 0.05 for
all comparisons). The results were consistent with pre-
vious data showing a lack of correlation between CRC-446
levels and disease stage, that low CRC-446 levels did not
result from the presence of a colorectal tumor, and
that CRC-446 levels were unaffected by any form of
treatment.
Effect of age on circulating levels of CRC-446 in control
subjects and CRC patients
The lack of correlation between serum CRC-446 levels
and tumor burden, in combination with the age-associated
increase in CRC incidence, prompted us to question the
possibility of a correlation between age and CRC-446
levels by assaying a random population of 990 control sub-
jects aged 11-99 collected at the provincial clinical testing
lab in Regina, Saskatchewan, Canada (SDCL, Table 1). A
significant inverse correlation between the concentration
of CRC-446 and age was observed in both the male and
female cohorts. Regression analysis (by gender) between
CRC-446 levels and age resulted in R values of 0.26 and
0.38, F-values of 48 and 55, and p-values of 8.4E-12 and
1.2E-12 for males and females, respectively (Table 2).
Similar analysis in the North American post-treatment
CRC patient population revealed no significant correlation
(regression R value of 0.11, F-value of 1.8 and p-value of
0.18; Table 2). The ten-year average decline (± 1 S.E.M) in
CRC-446 with age in the general population relative to
CRC positive subjects is shown in Figure 3A.
To investigate this age-related phenomenon further,
we defined the “optimal” CRC-446 level as greater than
Figure 2 CRC-446 levels in controls and CRC patients.( A )R O C
analysis based on CRC-446 concentrations across 150 Caucasian post-
treatment CRC patients and 761 age-matched controls. Dotted lines
represent the 95% confidence interval. Mean CRC-446 levels (± 1S.E.M)
are shown by disease stage for the 150 CRC patients (B) and by
treatment combination (C). p-values based on Student’s t-test between
all stages and between treatment comparisons were >0.05.
Table 2 Regression analysis between CRC-446 levels
and age
Cohort Multiple R F P-value
SDCL female controls 0.26 48 8.4E-12
SDCL male controls 0.38 55 1.2E-12
Bioserve CRC patients 0.11 1.8 0.18
Figure 1 CRC-446 levels in pre and post-surgery CRC patients.
Mean levels of CRC-446 in controls, pre-surgery and post-surgery
CRC patients as determined by triple-quadrupole tandem-MS for the
Osaka (A) and Chiba (B) studies. Levels are reported as
concentration equivalents (± 1 S.E.M in ug/ml), to the internal
standard [
13C1]cholic acid, (CAEs). p-values based on Student’s t-test
between pre- and post-surgery in both studies were >0.05. Note:
Control and pre-surgery levels were also previously reported in [14].
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50 (>0.18 ug/ml CAEs). The percent of subjects by dec-
ade of life falling into four quartiles centered around
this concentration (ie, <0.09, 0.09-0.18, 0.18-0.27 and
>0.27 ug/ml CAEs) were then determined and plotted as
s h o w ni nF i g u r e3 B .Ar e m a r k a b l ed e c l i n ei nt h e
percentage of subjects at each decade of life in the high-
est CRC-446 quartile is observed, with an increase in
the percent of subjects per decade of life in the middle
two quartiles. Relatively few subjects were present in the
lowest quartile. Specifically, the data indicate that 75%
of the under 50 age group have CRC-446 levels that are
in the top quartile (>0.27 ug/ml CAEs) while approxi-
mately 20% have levels in the second highest quartile
(0.18-0.27 ug/ml CAEs) and that approximately 5% have
levels in the bottom two quartiles (<0.18 ug/ml CAEs).
By age 70-79, the percent of subjects in the highest
quartile drops to nearly 50%, with over 35% of subjects
in the second highest quartile and over 10% in the low-
est two quartiles (Figure 3B). Interestingly, the sum of
the lowest three quartiles shows a nearly perfect inverse
correlation with the top quartile (correlation coefficient
of -0.999, not shown). The implications of these findings
are expanded upon in the final sections of the results
and discussion.
Longitudinal CRC-446 stability
Next we investigated the short-term intra-individual
variability of CRC-446. Eight healthy volunteers (four
females and four males, Table 1) were sampled frequently
over an approximate 90 week period. CRC-446 in these
subjects showed high intra-individual stability (Figure 4),
with an average percent CV of 7.6 ± 1.2% across the eight
subjects. All samplings from the eight subjects were con-
siderably higher than the average CRC patient levels
(above 0.15 ug/ml CAEs, dotted lines in Figure 4). A
similar analysis was performed longitudinally for up to 63
weeks on 12 stage IV CRC patients enrolled in a phase
IIb clinical trial for an experimental vaccine (Figure 5).
Although the intra-individual stability was higher in CRC
patients (average percent CV of 41.8 ± 22.3%), the rela-
tive CRC-446 levels were very low (average of 0.055 ±
0.003, ug/ml). The higher variability was likely due to the
very low CRC-446 signal-to-noise levels which were in
the lower detection range of the mass spectrometer. As
expected, in both the control and CRC longitudinal
cohorts, there were no statistically significant intra-indi-
vidual trends with time (all p for regression > 0.05). The
results show that in the short term, intra-individual
CRC-446 levels are relatively stable and resistant to acute
lifestyle factors such as diet. Collectively the results indi-
cate that CRC-446 levels do not randomly increase or
decrease in the population over time, but that either
population CRC-446 levels decline slowly over a rela-
tively long period of time or CRC-446 levels decline
rapidly due to some unknown acute event in a subset of
subjects and then remain stably low in these subjects for
long periods of time.
Figure 3 CRC-446 levels in controls and CRC patients by age.
(A) Mean CRC-446 levels (± 1 S.E.M.) by decade of life for the 990
controls (open squares) and for 150 CRC post-treatment patients
(open circles). (B) Percent of subjects by age group falling into four
CRC-446 quartiles centered around 50% of the under age 50 mean
concentration of 0.18 ug/ml CAE.
Ritchie et al. BMC Gastroenterology 2010, 10:140
http://www.biomedcentral.com/1471-230X/10/140
Page 5 of 11Impact of an age-associated biomarker on screening
The above results suggest that the increased prevalence
of low CRC-446 levels with age is a cumulative process.
This phenomenon creates a unique screening situation
in that, unlike other screening tests, the CRC-446 level
of a subject is influenced by both the previous test result
and the inter-test interval. For example, using a 0.23 ug/
ml CAE cut-off (selected to give an age-adjusted positiv-
i t yr a t eo fa p p r o x i m a t e l y1 0 %i nt h eS D C Lc o n t r o l
population aged 50 or less) the relationship between the
cumulative positivity rate, based on this cut-off, and age
for subjects aged <50, 50-59, 60-69 and 70-79 is linear
(Y = 0.65X-15.8, R2 = 0.98, Figure 6). The over 80 age
group was excluded from the model since screening
s u b j e c t so ft h i sa g eh a sq u e s t i o n a b l eb e n e f i t[ 2 1 ] .T h e
relationship between the increase in percent of subjects
with CRC-446 levels below 0.23 ug/ml CAEs by decade
of life and the increase in percent CRC incidence across
t h es a m ea g eg r o u p si sf u r t h e rs h o w ni nF i g u r e6 .T h e
slope of the line for CRC-446 levels by age was deter-
mined through linear regression to be 0.65 (with an R
2
of 0.98), corresponding to an annual increase in the
probability of having a CRC-446 level drop below 0.23
ug/ml CAEs of approximately 0.65% (or a 10-yr cumula-
tive probability of approximately 6.5%) given a prior
negative test. The implications of these findings on colo-
noscopy resources and CRC detection rates during the
projected lifetime CRC screening guidelines of the gen-
eral population are discussed below.
Discussion
Age is the most robust risk factor for the majority of
human diseases including cancer (Centers for Disease
Control and Prevention (http://www.cdc.gov 2010)).
Since most diseases likely have a long prodromal phase,
it is reasonable to postulate that causative biochemical
perturbations would begin to appear well before the
clinical onset of symptoms. Our previous findings that
the hPULCFA reduction in CRC patients was indepen-
dent of disease stage [14] prompted us to further inves-
tigate whether this reduction was also independent of
tumor burden, and if so, whether there was any correla-
tion between hPULCFA levels and age given the age
association with CRC incidence rates. The lack of CRC-
4 4 6r e s t o r a t i o ni nt w oi n d e p e n d e n tc o h o r t so fC R C
patients following surgery, and indistinguishable levels
between pre- and post-combination therapy reported
herein show that the reduction of circulating hPULCFA
levels in CRC patients is not due to the presence of can-
cer. A cross-sectional analysis of the general population
revealed a strong inverse association between age and
CRC-446 levels in average risk subjects but no age
Figure 4 Longitudinal CRC-446 levels in controls. Levels of CRC-
446 at multiple timepoints up to 90 weeks are shown for eight
healthy asymptomatic subjects. The dotted lines represent the
mean CRC-446 concentration in CRC-positive subjects of 0.15 ug/ml
CAEs for reference.
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Page 6 of 11Figure 5 Longitudinal CRC-446 levels in stage IV metastatic CRC patients. Levels of CRC-446 at multiple timepoints up to 63 weeks are
shown for 12 stage IV metastatic CRC patients enrolled in a clinical trial for an experimental cancer vaccine. The y-axes are scaled equivalently
to Figure 4 for comparison and the dotted lines represent the mean CRC-446 concentration in CRC-positive subjects of 0.15 ug/ml CAEs for
reference.
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healthy normals and late stage CRC subjects revealed
that within-subject CRC-446 levels are stable for at least
1 year. Together, these data support the conclusion that
hPULCFA levels decline prior to CRC development and
that the percentage of the population that exhibits this
decline increases with age. The cause of this decline is
unknown.
The above characteristics differentiate CRC-446 from
other CRC markers as many reported markers are
tumor-derived (i.e., fecal blood, transcripts, proteins,
methylated DNA, etc.). To investigate the screening
implications based on using CRC-446 for identifying ele-
vated CRC risk, we modelled the predicted outcomes of
a hypothetical cohort of 100,000 subjects living from age
30 to 80, and compared the impact on colonoscopy
resources and detection rates to that of fecal immunolo-
gical testing (FIT) (Table 3). The equation y = 0.65x-
15.8, generated from CRC-446 data reported in this
paper, was used to estimate per-decade age-specific
positivity rates for a typical screening population over a
50-year timeframe. We set a threshold that resulted in a
10% positivity rate in subjects under the age of 50 (0.23
ug/ml CAE), which is comparable to the Fecal Immuno-
chemical Test (FIT) [22]. Since the percent probability
of having an annual subsequent positive CRC-446 test
result when the first test was negative is only 0.65%, the
expected per-decade positivity rate (following an initial
negative test) would be 6.5%. Interestingly, using a
threshold this high resulted in an average test sensitivity
of 83.5% when applied to the BioServe post-treatment
CRC cohort (Table 3). Extrapolation of these positivity
rates to a theoretical biennial average risk screening
cohort of 100,000 would therefore result in approxi-
mately 30,000 positive CRC-446 test results and subse-
quent recommended follow-up colonoscopies. In
comparison (and everything else being equal), biennial
FIT testing would require 150,000 recommended follow
up colonoscopies (assuming a 10% positivity rate, Table
3) and would exclude subjects under age 50 based on
current guidelines. In fact, if the CRC-446 threshold was
raised to a point which resulted in 150,000 positive CRC
tests and subsequent follow up colonoscopies (five times
higher than the current model and equal to that of FIT),
the sensitivity of CRC-446 would be well over 90%. It is
critical to point out that a key difference between the
CRC-446 marker and a non age-related biomarker such
as FIT for screening is that increasing or decreasing the
frequency of CRC-446 tests (for example, to one every
five years rather than one every two years as modelled)
would not result in more follow up colonoscopies
required since the probability of a subsequent positive
test is simply the interval time × 0.65, whereas the 10%
positivity for FIT is independent of the interval time.
The impact on CRC detection rates was next esti-
mated across the 100,000 person cohort based on the
reported probability of developing CRC in the next dec-
ade of life (Canadian Cancer Statistics, 2009). Using the
decade-specific sensitivity rates reported for the Bio-
Serve population in this paper, approximately 4525 of
the estimated 5453 cases (83%) of the CRC cases would
be expected to be detected, while FIT (based on an age-
independent sensitivity of 60% per decade, but which
can vary widely depending on the study [23]), would
result in approximately 3254 positive detections. The
key points to these observations are: 1) the implementa-
tion of CRC-446 as a screening biomarker for CRC
would require significantly fewer follow-up colonosco-
pies than FIT, 2) more CRC cases would likely be
detected, 3) CRC cases under the age of 50 could be
detected which are currently missed, and 4) since there
is no bias between CRC-446 levels and disease stage,
there would be an enrichment in the number of early
stage cancers detected. The impact in terms of cost-ben-
efit could be substantial. For example, assuming similar
frequency and cost of CRC-446 versus FIT and a colo-
noscopy cost of $1000, the use of CRC-446 would result
in approximately $120 M in reduced follow-up colono-
scopy screening costs per 100,000 subjects. In addition,
Figure 6 Age-related CRC-446 positivity and CRC incidence
rates. Percent of SDCL control subjects by decade of life with CRC-
446 levels less than 0.23 ug/ml CAE (squares, primary y-axis). Linear
regression analysis (based on the median age of each decade of life
for the SDCL group) was used to determine the equation y = 0.65x-
15.8, representing a .65% annual probability of a positive test result
(concentration less than 0.23 ug/ml CAE) given a prior negative test
(concentration greater than 0.23 ug/ml CAE). For comparison, the
incidence rate of CRC as a percent of each age group (based on
Canadian Cancer Statistics, 2009), is shown (circles, secondary axis).
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late into reduced healthcare burden simply due to the
lower direct cost of treating early-versus late-stage can-
cer, as well as the indirect cost savings associated with
decreased mortality. However, detailed cost-benefit ana-
lyses for individual geographic regions would be
required to accurately forecast the economic health-bur-
den impact of CRC-446 screening. Unfortunately, the
lack of correlation between CRC-446 levels and any
form of treatment suggests that CRC-446 would likely
not be suitable for monitoring treatment response.
However, whether CRC patients with “normal” CRC-446
levels (i.e., false negatives) have a different prognostic
outcome than CRC subjects with low CRC-446 levels
remains to be determined.
Although the origin of hPULCFAs, including CRC-446,
is currently unknown, they are structurally similar to the
fatty acid-derived long-chain hydroxylated resolvins
[24-26] and protectins [27-29], which are mediators
involved in the resolution of acute inflammation. The fail-
ure to resolve acute inflammation can lead to a chronic
inflammatory state, a well known underlying component
of CRC development [30] whichi st h eb a s i sf o rc h r o n i c
low-dose preventative NSAID use [31,32]. The possibility
that CRC-446, or other hPULCFAs may be to some extent
implicated in mediating endogenous anti-inflammatory
responses cannot be excluded at this time, and further stu-
dies will be required to investigate any role(s) that these
molecules may play in inflammation.
There are several limitations to the results reported
here. The age-related decline is based upon single point
cross-sectional data, and the longitudinal studies were
insufficiently powered to accurately determine the long-
term rate of intra-individual decline in the general
population. The design was sufficient to determine
short-term intra-subject CRC-446 stability but not long-
term CRC-446 instability, and thus we were unable to
distinguish between a slow decline process versus a
rapid decline followed by subsequent long-term stability.
Ultimately longitudinal tracking of thousands of subjects
over several decades will be required to determine intra-
individual rates of hPULCFA decline. This age-related
phenomenon is not observed for other CRC screening
modalities including fecal blood, which shows no corre-
lation between age and test positivity [33].
The fact that reduction of hPULCFAs in CRC patients
does not correlate with disease stage, that the reduction
is not affected by surgery or treatment, and that an
average population shows an age-related reduction
which correlates with the incidence of the disease, sug-
gests that the reduction of hPULCFAs occurs prior to
and is independent of the presence of the cancer. Such
a disease risk marker is indeed unique in the CRC field.
Conclusions
The results presented herein confirm our previous report
that low circulating levels of CRC-446 is a sensitive serum
biomarker for CRC presence and that the low CRC-446
levels observed in CRC subjects are independent of tumor
burden or the subject’s age. In a representative non-CRC
population, declining CRC-446 levels were observed to
exhibit a strong age-association. CRC-446 reduction in
non-CRC subjects, therefore, may represent an elevated
risk for subsequent CRC development. Due to the sensitiv-
i t ya n dt h ec u m u l a t i v en a t u r eo ft h eo b s e r v e dC R C - 4 4 6
deficiency, a CRC screening program based upon serum
Table 3 Comparison of test positivity rates and recommended follow-up procedures based on CRC-446 (<0.23 ug/ml
CAEs) and FIT
Age Actual CRC-446
test positivity (%
by decade) for
SDCL controls
(<0.23 ug/ml)
Theoretical CRC-446
positivity
(incremental % by
decade
1
) for SDCL
controls (y = 0.65x-
15.8)
Actual
Bioserve CRC
positivity (%
by decade
using <0.23
ug/ml)
Estimated
follow-up
colonoscopies
per decade
based on CRC-
446 test
3
Estimated
follow-up
colonoscopies
per decade
based on
biennial FIT
4
Expected
incidence
from
initial
100,000
6
CRC-446
test
estimated
CRC
detections
7
FIT test
estimated
detections
8
<50 12.3 10
2 88.2 10,000 0 250 220 132
50-59 21.7 6.5 81.8 6,500 50,000 695 569 417
60-69 26.8 6.5 78.7 6,500 50,000 1684 1326 1010
70-79 32.3 6.5 85.3 6,500 50,000 2824 2409 1694
(Average)
Total
(83.5) 30,000 150,000 5453 4523 3254
1Based on equation y = 0.65x-15.8 fitted to SDCL control data per decade falling below CRC-446 levels of 0.23 ug/ml.
2First CRC-446 test positivity (adjusted to mean of age 30 to 50).
3Note that number of positive CRC-446 tests is independent of testing frequency. Values shown are for per decade cumulative risk and assume all CRC-446
positive subjects have colonoscopy.
4Based on performing one FIT test every two years with 10% positivity rate (assuming all FIT positive subjects have colonoscopy).
6Based on the probability of developing cancer by decade of life (2009 Canadian Cancer Stats).
7Based on reported Bioserve CRC decade-specific positivity rates.
8Based on an average sensitivity of 60% per decade.
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Page 9 of 11CRC-446 depletion is projected to detect more CRC sub-
jects with fewer colonoscopies required per subject
screened. Further studies to unambiguously demonstrate a
causal relationship between reduced circulating hPULCFA
levels and CRC are warranted.
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